Evelyn Mullen, chief operating officer for Global Security at Los Alamos National Laboratory, was named a fellow of the American Nuclear Society.
LOS ALAMOS, N.M., Oct. 13, 2020–Evelyn Mullen, chief operating officer for Global Security at Los Alamos National Laboratory, was named a fellow of the American Nuclear Society for her leadership in nuclear national security and ensuring the nation’s experimental capability in nuclear criticality.
“For more than 25 years, Evelyn Mullen has displayed outstanding leadership in nuclear and radiological threat response,” said Nancy Jo Nicholas, associate Laboratory director for Global Security at Los Alamos. “She has provided intellectual leadership for planning and executing science and technology for nuclear nonproliferation, detection, render safe, and attribution; foreign nuclear weapon analysis; and nuclear detonation response and recovery issues. Being named an ANS Fellow is a well-deserved honor for someone who has contributed so much
While Making Strides events have gone virtual this year, Chevrolet will continue support the events at the national, regional and local level all month. Employees across the country are participating in local Making Strides Against Breast Cancer events by “walking where they are” and making donations.
On October 1, Chevrolet launched its monthlong #IDriveFor social media campaign, which encourages people to share whom they drive for using the hashtag. Chevrolet will contribute $5 for every social post (up to $220,000) on Twitter or Instagram using #IDriveFor.
Chevrolet is also showing its support for Breast Cancer Awareness Month and Making Strides by turning the towers of the Renaissance Center global headquarters in Detroit pink during October, displaying a pink fleet of vehicles and painting the sidewalks in front of the Renaissance Center pink.
“We are more grateful than ever for Chevrolet’s partnership, 10 years strong,” said Gary Reedy,
WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer will present detailed results from the Phase III FIDELIO-DKD study assessing the use of the investigational drug finerenone on kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) during scientific sessions of the upcoming American Society of Nephrology’s (ASN) Kidney Week, October 22-25, 2020. Additional data evaluating use of finerenone will also be presented.
The FIDELIO-DKD study, which evaluated the efficacy and safety of finerenone versus placebo when added to standard of care in patients with CKD and T2D, is the first large contemporary positive outcomes study in patients with CKD and T2D with a primary composite endpoint exclusively consisting of kidney-specific outcomes. Bayer announced earlier this year that FIDELIO-DKD met its composite primary renal endpoint and its composite key secondary cardiovascular endpoint.
Full data from the FIDELIO-DKD study will be presented as part of the live-streamed, late-breaker
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data were featured in two oral presentations during the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, Oct. 9-11, 2020.
DecisionDx®-Melanoma: Skin Cancer and Reconstruction Session; Friday, October 9, 2020
“Cutaneous Melanoma Prognostic Model Combining 31-gene Expression Profile and Sentinel Lymph Node Biopsy” was presented by Aaron Farberg, M.D., Baylor University Medical Center, Dallas, Texas.
DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors.
“As most sentinel lymph node biopsies are negative, there is a need to identify which melanoma patients can forgo sentinel lymph node biopsy (SNLB),” said Dr.
JERUSALEM, Oct. 12, 2020 /PRNewswire/ — KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that an abstract reporting preclinical data for DSP107, a second generation CD47x41BB targeting compound for the treatment of solid tumors and hematological malignancies, has been accepted for an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5-8, 2020.
“The ASH Annual Meeting will be an important opportunity to present mechanistic studies and extensive in vitro and in vivo results from our novel CD47x41BB clinical stage drug candidate,” said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. “We look forward to advancing the clinical development of this novel therapy.”
The following abstract will be posted on the ASH website on November 5, 2020, at 9:00 a.m. ET:
Title: DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition
On paper at least, the American Horticultural Society, founded in 1922, should be poised to move into its second century as a major player in the green world, an organization with a compelling mission and a rosy future.
The pandemic has reinforced the importance of gardens and gardening, reflected in surging vegetable seed sales and the desire of people to visit public gardens and other green spaces to find succor in anxious times.
COVID-19 aside, public gardens offer enormous potential to connect an ever urbanizing population to a planet in environmental crisis and to bring together diverse groups at a time of social, political and economic unrest.
But the AHS, located at its pastoral 25-acre property on the Potomac, River Farm, is facing its own moment of reckoning.
Citing the pandemic as a contributor, the society recently announced on its website that it was considering leaving River Farm, merging in
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it has authored or sponsored 12 presentations at the upcoming American Society of Nephrology (ASN) Kidney Week 2020 being held virtually October 22-25, 2020. Data to be presented at multiple sessions at the meeting will expand the breadth of information about the implications of metabolic acidosis and CKD. All Tricida presentations will be available on Thursday, October 22, 2020 at 10:00am ET. Session and presentation titles are listed below:
Session Title: CKD Risk Factors: Diet, Environment, Lifestyle
Relationship Between Metabolic Acidosis and Chronic Kidney Disease Progression is Evident Across United States Racial and Ethnic Groups
N. Tangri et al.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that clinical data on nedosiran, an investigational candidate for the treatment of primary hyperoxaluria (PH), will be presented during the American Society of Nephrology (ASN) Kidney Week taking place Oct. 22-25, 2020. In addition, a commercial claims analysis of clinical and economic burden associated with PH will also be presented.
The following poster presentations will be available during the “Genetic Diseases of the Kidneys: Non-Cystic – 1” session taking place on Thursday, Oct. 22, 2020 at 10:00 a.m. ET:
Title: PHYOX™3: A Long-Term, Open-Label Extension Trial of Nedosiran in Patients With Primary Hyperoxaluria Type 1, 2 or 3
Poster #: PO1625
About Primary Hyperoxaluria
Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. There are three known types of
Richard Kaner, who is the Dr. Myung Ki Hong Professor of Materials Innovation, has been elected a 2020 fellow of the American Physical Society, a nonprofit organization that advances the knowledge of physics and represents more than 55,000 members worldwide, including physicists in universities, national laboratories and industry.
The society selected 163 fellows in late September and praised Kaner for “outstanding contributions to the physics, chemistry, and materials science of nanostructured conducting polymers, superhard metals, and new forms of carbon including superconducting fullerides, carbon nanoscrolls, and graphene.” Kaner is a distinguished professor of chemistry and biochemistry, and of materials science and engineering, and a member of the California NanoSystems Institute at UCLA.
Kaner and his research team have designed a series of remarkable devices. One device creates electricity from falling snow. Kaner and UCLA researcher Maher El-Kady, call the device a snow-based triboelectric nanogenerator, or snow TENG, and reported this
IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ — Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020.
The scheduled times (noted in local Eastern Standard Time) of the presentations, titles and authors are as follows.
Oral presentations include:
- Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers: A Pooled Analysis
- Authors: Joely Kaufman, Patricia Ogilvie, Kenneth Beer, Alexander Rivkin, Sarah Baradaran, Andrew Schumacher
- Presenter: Joely Kaufman, MD
- Saturday, October 10th, 11:27 a.m.
- Authors: Joel L. Cohen, Koenraad De Boulle, Steven Fagien, Jean Carruthers, Sue Ellen Cox, Patricia Ogilvie, Julie Garcia, Sara Sangha
- Presenter: Joel L. Cohen, MD
- Sunday, October